Global Community

HOLDS MORE CASH THAN DEBT ON ITS BALANCE SHEET

HOLDS MORE CASH THAN DEBT ON ITS BALANCE SHEET

The company has demonstrated exceptional earnings growth in H1 2025, backed by operational leverage, prudent cost control , and a healthy balance sheet. Despite agricultural seasonality and inflationary pressures, Okomu Oil's performance suggests continued upside potential in the near-to-medium term.

Presco Plc Delivers Explosive Earnings Growth in H1 2025 – A High-Yield, High-Confidence Investment Case Presco Plc’s H1 2025 results reveal a remarkable earnings story driven by record revenue growth, margin expansion, and consistent operational strength. With a 125.8% surge in revenue and a 128.2% boost in net profit, Presco has firmly established itself as a top-tier performer in Nigeria’s agro-industrial sector.

NGX Group Plc delivered a robust performance in H1 2025, posting profit after tax of ₦4.22 billion , representing a significant growth of 97% compared to ₦2.14 billion in H1 2024. This sharp rebound highlights the resilience of NGX’s diversified earnings streams and the strength of its capital market infrastructure business amidst recovering macroeconomic conditions.

Nestlé Nigeria Plc has staged a remarkable recovery in H1 2025, reversing the prior year’s losses with impressive revenue and profit growth. A combination of robust top-line performance, margin expansion, and efficient cost control drove a swing from a ₦252.5 billion pre-tax loss in H1 2024 to an ₦88.4 billion profit in H1 2025.

Nigerian Breweries Plc has delivered a remarkable turnaround in H1 2025, swinging from a ₦85.2 billion loss in H1 2024 to an ₦88.4 billion profit. This performance reflects a combination of strong revenue growth, disciplined cost management, and sharply lower finance costs, positioning the company for a more stable and profitable future despite lingering macroeconomic pressures.

Robotics and artificial intelligence are rapidly transforming industries from manufacturing to healthcare. BOTZ provides diversified exposure to companies leading this change — including hardware (robot arms), automation software, and AI chips.

Duopharma Biotech Bhd (KLSE: DPHARMA, ticker 7148) Healthcare – Pharmaceuticals / Biotech Investment Review Recommendation: HOLD (Initiated) Key Metrics Company Overview Duopharma Biotech Bhd is a leading pharmaceutical manufacturer in Malaysia, involved in the research, development, manufacturing, and distribution of generic and specialty pharmaceutical products. Its operations span: Ethical Classic : General therapeutic generics (e.g., cardiovascular, anti-infectives) Ethical Specialty : Bio-similars for oncology, renal, and metabolic diseases Consumer Healthcare (CHC) : Notable OTC brands like Champs, Flavettes, and Uphamol As of 2025, it exports to multiple countries and operates from 3 GMP-certified manufacturing facilities.